

Division of Signal Tranduction Therapy

Standard Operating Procedure

Preparation of active Lck [2 - 509]

<u>Enzyme description:-</u>	Lck [2 - 509]
<u>Clone number:-</u>	DU 567
<u>Source:-</u>	Recombinant
<u>Expression system:-</u>	Baculovirus expression vector system
<u>Tag:-</u>	N-terminal His(6)
<u>Purification method:-</u>	Ni ²⁺ -NTA agarose
<u>Expression level:-</u>	2 mg/L
<u>Calculated molecular mass:-</u>	64, 734 daltons
<u>Purity:-</u>	>85 %
<u>Activation protocol:-</u>	Constitutively active
<u>Enzyme storage buffer:-</u>	50 mM Tris-HCl pH 7.5, 50 % glycerol, 150 mM NaCl, 0.1 mM EGTA, 0.1 % 2-mercaptoethanol, 0.02 % Brij-35, 0.2 mM PMSF, 1 mM Benzamidine.
<u>Storage temperature:-</u>	-20 °C
<u>Assay:-</u>	Standard filter binding assay
<u>Assay buffer:-</u>	50 mM Tris-HCl pH 7.5, 0.1 % 2-mercaptoethanol, 0.1 mM EGTA, 10 mM MgAc
<u>Substrate:-</u>	KVEKIGEGTYGVVYK [Residues 5 – 20 of human CDK2] Final concentration: 250 µM
<u>Specific activity range:-</u>	700 – 1400 U/mg

Division of Signal Transduction Therapy

Clone Data Sheet

Lck [2 - 509]

<u>Protein</u>	Lck [2 - 509]
<u>Clone number</u>	DU 567
<u>Species</u>	Mouse
<u>Accession no</u>	X03533
<u>Tags</u>	N-terminal His(6)
<u>Baculovirus expressed protein</u>	MSYYHHHHHDYDIPPTENLYFQGAMDPEFGC G CSS H PEDDWME NIDVCENCHYPIVPLDSKISLPIRNGSEVRDPLVTYEGSLPPAS PLQDNLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSL TTGQEGFIPFNFKVAKANSLEPEPWFFKNLSRKDAERQLLAPGNT HGSFLIRESESTAGSFSLSVRDFDQNQGEVVKHYKIRNLNDNGGF YISPRITFPGLHDLVRHYTNASDGLCTKLSRPCQTQKPQKPWWE DEWEVPRETLKLVERLGAGQFGEVWMGYYNHTKAVKSLKQGS MSPDAFLAEANLMQLQHPRLVRLYAVVTQEPIYIITEYMENG LVDFLKTPSGIKLNVNKLLDMAAQIAEGMAFIEEQNYIHRDLRA ANILVSDTLSCKIADFGHLARLIEDNEYTAREGAKFPIKWTAPEA INYGTFTIKSDVWSFGILLTEIVTHGRIPYPGMTNP GYRMVRPDNCPEELYHLMMLCWKERPEDRPTFDYLR ATEGQYQPQPVDL
<u>Native sequence</u>	Amino acids G2 – P509 (end) of mouse Lck. Residue G31 of the fusion protein is equivalent to G2 of mouse Lck. The His(6) tag is located at residues 5 – 10. The following sequence is present after the Lck sequence, VDL, residues 539 – 541. The following amino acid substitutions are present: V – G , where V4 of the native sequence is G33 of the fusion protein. N – H , where N8 of the native sequence is H37 of the fusion protein.
<u>Protease cleavage</u>	rTEV (<u>ENLYFQG</u>) residues 18 - 24
<u>Cloning sites</u>	<i>Eco</i> R1 and <i>Not</i> 1 sites of pFastBAC HTa

Division of Signal Tranduction Therapy

Nucleotide sequence of insert

GAATTGGCTGTGGCTGCAGCTCACACCCCTGAAGATGACTGGATGGAGAA
CATTGACGTGTGAAAACGCCACTATCCCCTAGTCCCCTGGACAGCA
AGATCTCGCTGCCCATCCGAATGGCTCTGAAGTGCGGGACCCACTGGTC
ACCTATGAGGGATCTCTCCCACCAGCATCCCCGCTGCAAGACAAACCTGGT
TATCGCCCTGCACAGTTATGAGCCCTCCCATGATGGAGACTTGGGCTTTG
AGAAGGGTGAACAGCTCGAATCCTGGAGCAGAGCGGTGAGTGGTGGAAAG
GCTCAGTCCCTGACGACTGGCCAAGAAGGCTTCATTCCCTCAACTCGT
GGCGAAAGCAAACAGCCTGGAGCCTGAACCTGGTTCTCAAGAACATTGA
GCCGTAAGGACGCCAGCGCAGCTTGGCGCCGGAACACGCATGGA
TCCTTCCTGATCCGGAAAGCGAAAGCACTGCAGGGTCCTTCCCTGTC
GGTCAGAGACTTCGACCAGAACCAAGGGAGAAGTGGTGAACATTACAAGA
TCCGTAACCTAGACAACGGTGGCTCTACATCTCCCTCGTATCACTTT
CCCGGATTGCACGATCTAGTCCGCCATTACACCAACGCCCTGATGGGCT
GTGCACAAAGTTGAGCCGTCCTGCCAGACCCAGAACGGGAAACACTGAAGTGGTGGAG
CGGCTGGGAGCTGGCAGTTGGGAAGTGTGGATGGGTACTAACACGG
ACACACGAAGGTGGCGGTGAAGAGTCTGAAACAAAGGGAGCATGTCCCCG
ACGCCCTCCTGGCTGAGGCTAACCTCATGAAGCAGCTGCAGCACCCGCG
CTAGTCCGGCTTATGCAGTGGTACCCAGGAACCCATCTACATCATCAC
GGAATACATGGAGAACGGGAGCCTAGTAGATTCTCAAGACTCCCTCGG
GCATCAAGTTGAATGTCAACAAACTTTGGACATGGCAGCCAGATTGCA
GAGGGCATGGCGTTCATCGAAGAACAGAATTACATCCATGGGACCTGCG
CGCCGCCAACATCCTGGTGTCTGACACGCTGAGCTGCAAGATTGAGACT
TTGGCCTGGCGCGCTCATTGAGGACAATGAGTACACGGCCGGAGGGG
GCCAAATTCCCATTAAAGTGACAGCACCAGAACCCATTAACTATGGGAC
CTTCACCATCAAGTCAGACGTGTGGCTTCGGGATTTGCTTACAGAGA
TCGTCACCCACGGTCGAATCCCTTACCCAGGAATGACCAACCTGAAGTC
ATTCAAGAACCTGGAGAGAGGGTACCGCATGGTGAGACCTGACAACTGTCC
GGAAGAGCTGTACCACCTCATGATGCTGTGGAGGGAGCAGGCCAGAGG
ACCGGCCACGTTGACTACCTCGGAGTGTCTGGATGACTTCTTCACA
GCCACAGAGGGCCAGTACCAGCCCCAGCCTGTCGACCTCtaggcggccgc